Opus Genetics officer auto-sells shares for taxes

Opus Genetics, Inc. Chief Scientific & Dev.

Rhea-AI Filing Summary

Opus Genetics, Inc. Chief Scientific & Dev. Officer Jayagopal Ashwath reported an automatic sale of common stock tied to tax obligations. On this Form 4, 7,542 shares were sold in an open-market transaction at a weighted average price of $5.1917 per share.

According to the footnotes, the sale was executed automatically by the company to satisfy tax withholding arising from a restricted stock unit vesting and settlement, and was not a discretionary trade. After the sale, Ashwath directly owns 509,233 shares of Opus Genetics common stock.

Insider Trade Summary

Net Seller: 7,542 shares

Net Sell 1 txn

Insider Jayagopal Ashwath

Role Chief Scientific & Dev. Ofc.

Sold 7,542 shs ($39K)

Type	Security	Shares	Price	Value
Sale	Common Stock	7,542	$5.1917	$39K

Holdings After Transaction: Common Stock — 509,233 shares (Direct)

Footnotes (2)

1. F1. The shares reported on this line were sold automatically on behalf of the Reporting Person, as required by the Company to satisfy tax withholding obligations that arose in connection with a vesting and settlement event from a restricted stock units award. This transaction does not represent a discretionary trade by the Reporting Person.
2. F2. The price in column 4 represents the weighted average price. The shares were sold in multiple transactions at prices ranging from $5.18 to $5.21, inclusive. The Reporting Person undertakes to provide the issuer, any securityholder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

Key Figures

Shares sold: 7,542 shares Average sale price: $5.1917 per share Shares owned after sale: 509,233 shares +1 more

4 metrics

Shares sold 7,542 shares Open-market sale on 2026-04-23

Average sale price $5.1917 per share Weighted average for the 7,542 shares sold

Shares owned after sale 509,233 shares Direct holdings following the transaction

Sale price range $5.18–$5.21 per share Range of individual trade prices disclosed

Key Terms

restricted stock units, tax withholding obligations, weighted average price

3 terms

restricted stock units financial

"a vesting and settlement event from a restricted stock units award"

Restricted stock units are a type of company reward where employees are promised shares of stock, but they only fully own these shares after meeting certain conditions, like staying with the company for a set time. They matter because they can become valuable assets and are often used to motivate employees to help the company succeed.

tax withholding obligations financial

"sold automatically ... to satisfy tax withholding obligations that arose"

weighted average price financial

"The price in column 4 represents the weighted average price."

Weighted average price is the average price of a security where each trade or component is counted according to its size, so bigger trades pull the average more than smaller ones. Think of it like calculating the average cost of a grocery haul where items you bought more of have greater influence on the final per-item cost. Investors use it to understand the true average price paid or received, judge execution quality, and compare trading performance against market movement.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transaction did Opus Genetics (IRD) report for Jayagopal Ashwath?

Opus Genetics reported that Chief Scientific & Dev. Officer Jayagopal Ashwath sold 7,542 shares of common stock. The sale was automatic to cover tax withholding from a restricted stock unit vesting event and was not a discretionary trade by the executive.

Was the Opus Genetics (IRD) insider sale by Jayagopal Ashwath a discretionary trade?

No, the filing states the transaction was not discretionary. Shares were sold automatically by the company to satisfy tax withholding obligations triggered by a restricted stock unit vesting and settlement, rather than through a voluntary market-timing decision by Ashwath.

How many Opus Genetics (IRD) shares did Jayagopal Ashwath sell and at what price?

He sold 7,542 shares of Opus Genetics common stock. The weighted average sale price was $5.1917 per share, with multiple trades executed in a range from $5.18 to $5.21, as disclosed in the Form 4 footnotes.

How many Opus Genetics (IRD) shares does Jayagopal Ashwath own after this Form 4 transaction?

After the reported sale, Jayagopal Ashwath directly owns 509,233 shares of Opus Genetics common stock. This post-transaction holding shows he retained a substantial equity position in the company following the tax-related share sale.

Why did Opus Genetics (IRD) sell shares on behalf of Jayagopal Ashwath?

Shares were sold automatically to cover tax withholding obligations from a restricted stock unit award vesting and settling. The company required this sale to satisfy associated tax liabilities, making it an administrative transaction rather than a voluntary market sale.

What price range is disclosed for the Opus Genetics (IRD) insider share sales?

The Form 4 notes a weighted average sale price of $5.1917 per share. Individual trades occurred at prices ranging from $5.18 to $5.21, and the reporting person offered to provide full breakdowns of volumes at each price upon request.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 04/27/2026 - 04:26 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Jayagopal Ashwath

(Last) (First) (Middle)

C/O OPUS GENETICS, INC.

8 DAVIS DRIVE, SUITE 220

(Street)

DURHAM NORTH CAROLINA 27713

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Opus Genetics, Inc. [ IRD ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Scientific & Dev. Ofc.

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
04/23/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	04/23/2026		S(1)		7,542	D	$5.1917(2)	509,233	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. The shares reported on this line were sold automatically on behalf of the Reporting Person, as required by the Company to satisfy tax withholding obligations that arose in connection with a vesting and settlement event from a restricted stock units award. This transaction does not represent a discretionary trade by the Reporting Person.

2. The price in column 4 represents the weighted average price. The shares were sold in multiple transactions at prices ranging from $5.18 to $5.21, inclusive. The Reporting Person undertakes to provide the issuer, any securityholder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

	/s/ Amy Rabourn, by Power of Attorney	04/27/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)